TipRanks on MSN

Recursion Pharmaceuticals Registers Resale of 7 Million Shares

The latest announcement is out from Recursion Pharmaceuticals ( ($RXRX) ). On November 26, 2025, Recursion Pharmaceuticals filed a prospectus ...
GEN - Genetic Engineering and Biotechnology News

Recursion’s Incoming CEO on Turning AI Drugs Into Clinical Proof Points

Najat Khan, PhD, unpacks realistic timelines for AI-based drugs to make clinical impact and her priorities for Recursion as incoming CEO.

Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025

Ongoing Phase 1b/2 Trial of the Allosteric MEK1/2 Inhibitor REC-4881 as Monotherapy (FAP): Updated Safety and Efficacy Najat Khan, Ph.D ., Chief R&D and Chief Commercial Officer and incoming CEO and ...

Is the Market Bullish or Bearish on Recursion Pharmaceuticals Inc?

Recursion Pharmaceuticals Inc's (NYSE: RXRX) short interest as a percent of float has fallen 15.85% since its last report.
American Association of Individual Investors

Which Is a Better Investment, Immunocore Holdings plc or Recursion Pharmaceuticals, Inc. Stock?

Learn more about whether Immunocore Holdings plc or Recursion Pharmaceuticals, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.
The Bakersfield Californian

Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial ...

Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, announced today that it will present ...